Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

31,147 trials

NCT07244393
Recruiting
Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
Phase 1 · South Korea · 1 site
Registry update: 7 Oct 2026
NCT06412120
Recruiting
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
Phase 4 · Nigeria, United States · 4 sites
Registry update: 5 Aug 2026
NCT07777484
Recruiting
An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination.
Phase 1 · Austria · 1 site
Registry update: 10 Sept 2026
NCT07581795
Recruiting
Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer
Phase 2 · China · 1 site
Registry update: 2 Nov 2026
NCT07731776
Recruiting
Improving Access to Pelvic Health Physiotherapy for Endometriosis
Not applicable · Canada · 1 site
Registry update: 30 Jul 2026
NCT07227779
Recruiting
BPaLMZ for TB Meningitis
Phase 2 · Uganda · 2 sites
Registry update: 16 Oct 2026
NCT07688213
Recruiting
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
Phase 2 · Australia, Canada, China, Germany, Spain, United Kingdom, United States · 35 sites
Registry update: 6 Nov 2026
NCT07731139
Recruiting
A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have Obesity
Phase 1 · United States · 1 site
Registry update: 23 Sept 2026
NCT07663136
Recruiting
Finding Immune Nascent Type 1 Diabetes
Not applicable · United States · 1 site
Registry update: 2 Oct 2026
NCT07586202
Recruiting
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Phase 2 · Canada, China, Spain, South Korea, Taiwan, United States · 27 sites
Registry update: 3 Nov 2026
2024-519133-29-00
Recruiting
Efficacy of probenecid on cluster seizures during dosage reduction of Anti Seizure Medication (ASM) in presurgical focal epilepsy video-EEG monitoring
Phase 2 · France · 10 sites
Registry update: 1 Oct 2026
NCT07514858
Recruiting
A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations
Phase 2 · Czechia, Germany, Spain, France, Italy, Poland, Sweden, United States · 27 sites
Registry update: 8 Sept 2026
NCT07659795
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Phase 2 · Australia, United States · 30 sites
Registry update: 26 Oct 2026
NCT07680452
Recruiting
Clinical Study on High-fiber Diet and Short-term Fasting in Melanoma Under Immunotherapy With Checkpoint Inhibition
Not applicable · Germany · 1 site
Registry update: 29 Jul 2026
NCT07444515
Recruiting
Prospective Analysis of Self Medication With Phytotherapy in Nephropatic Patients.
Not applicable · France · 4 sites
Registry update: 16 Sept 2026
NCT07864207
Recruiting
Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)
Phase 1/2 · Spain · 10 sites
Registry update: 7 Oct 2026
2026-525917-29-00
Recruiting
Early TRIPLE versus dual LIPID lowering treatment in peOple with atherosclerotic cardiovascular disease and hypercholesterolemia Undergoing elecTive revascularisation
Phase 4 · Austria, Germany · 7 sites
Registry update: 17 Jul 2026
NCT07685808
Recruiting
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Phase 2 · United States · 21 sites
Registry update: 6 Nov 2026
NCT06118983
Recruiting
Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)
Not applicable · United States · 2 sites
Registry update: 21 Aug 2026
2025-523087-20-00
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
Phase 3 · Belgium, Germany, Spain, France, Italy, Netherlands, Poland · 17 sites
Registry update: 27 May 2026

Ordered by registry start date. Freshness and sponsorship never change the order.